MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Study: Kips Bay begins U.S. feasibility trial for vascular mesh

Study: Kips Bay begins U.S. feasibility trial for vascular mesh

By

Kips Bay Medical logo

Kips Bay Medical (NSDQ:KIPS) launched the 1st feasibility trials aimed at gaining FDA investigational device clearance for its eSVS vascular mesh.

The eSVS is designed to help keep vein grafts open in patients undergoing coronary artery bypass surgery, according to the company’s brochure.

The device is comprised of a flexible, knitted sleeve that fits around the outside of the vein in order to reduce vessel wall stress and mitigate the potential for vessel injury.

Minneapolis-based Kips Bay plans to launch the eMesh I study in order to demonstrate the initial safety and performance of the eSVS mesh in order to obtain FDA approval to run a pivotal study.

The company further noted that it was forming its response to the FDA’s rejection of its previous IDE application.

In September 2011 the FDA issued Kips Bay a non-approvable letter, asking for more information on the eSVS mesh before granting IDE approval for perform pivotal human trials.

That decision sent KIPS shares plummeting 34% to an new all-time low in a single day.

The FDA had rejected Kips request for permission to add 4 U.S. sites to its ongoing feasibility trials. The federal watchdog agency asked for more information on pre-clinical testing design testing for the mesh, which Kips plans to provide within 30 days of filing its amended IDE application, according to an SEC filing.

"If the FDA approves the amended IDE Application, U.S. physicians will then be allowed to begin enrolling patients," according to the filing. "Kips Bay Medical has already contacted prominent U.S. heart centers that are taking steps to secure internal approvals of their institutional review boards and administration/finance departments to participate in the study."

"Despite the FDA response, we have received a significant level of interest and excitement about our eSVS Mesh by several leading U.S. cardiac surgeons who we recently introduced the product to in anticipation of a potential study here in the U.S." Kips Bay founder Manny Villafaña said in prepared remarks. "Their high level of interest in and eagerness to study the eSVS Mesh is a tremendous motivator for me, and the Kips Bay team, to ensure that the clinical study of the eSVS Mesh is performed properly in both the U.S. and Europe."

In case you missed it

RSS From Medical Design & Outsourcing

  • Protolabs reports mixed-bag results for Q2
    Protolabs (NYSE: PRLB) posted second-quarter earnings today that missed the consensus forecast on Wall Street, though the company beat on revenue. The Maple Plain, Minn–based digital manufacturing outsourcer — which serves medtech and a host of other industries — reported profits of $12.9 million, or 47¢ per share, on sales of $123.0 million for the… […]
  • Integer beats The Street in Q2, boosts sales outlook
    Integer Holdings (NYSE:ITGR) posted second-quarter results today that beat the consensus forecast on Wall Street — boosting its 2021 sales outlook amid continued recovery from the COVID-19 pandemic. The Plano, Texas–based medical device contract manufacturing giant reported profits of $29.4 million, or 89¢ per share, on sales of $312.0 million for the three months ended… […]
  • Keep the end in mind when choosing a medtech partner
    There are five general categories of medtech vendor partners. If the end is apparent in the beginning, the correct type of partner will be more apparent. Jim Reed, Minnetronix Medical Stephen Covey gave the business world this mantra in one of his bestsellers: “Start with the end in mind.” Whether they didn’t read the book… […]
  • Orthofix launches Fiberfuse Strip bone graft
    Orthofix (NSDQ:OFIX) today announced that it has launched its FiberFuse Strip bone graft in the U.S. Lewisville, Texas–based Orthofix designed the FiberFuse Strip to be a preformed bone-graft strip for posterior cervical, posterior lumbar and degenerative spinal procedures. FiberFuse Strip is 100% bone and has a unique mixture of mineralized cancellous and demineralized cortical bone with… […]
  • Thermo Fisher Scientific beats The Street in Q2 results
    Thermo Fisher Scientific (NYSE:TMO) today posted second-quarter results that beat the overall consensus on Wall Street. The Waltham, Mass.–based company reported profits of $1.8 billion, or $4.61 per share, on sales of $9.3 billion for the three months ended July 1, 2021, for a bottom-line gain of 58.1% on sales growth of 34.1% compared with… […]
  • Choosing the Right Rubber Material and Process for Your Medical Parts
    When it’s time to design and develop a new medical device that calls for an elastomer component, there are a number of material options and manufacturing processes to consider. The long list of material properties impacting performance includes your prospective polymer’s end-use environment, chemical compatibility, hardness, compression set, tensile properties and manufacturability — to name… […]
  • 3M’s healthcare segment registers growth in Street-beating Q2
    3M (NYSE:MMM) reported second-quarter results that beat the consensus forecast — with the company’s healthcare segment showing especially robust growth. The St. Paul, Minn.–based company posted profits of $1.5 billion, or $2.59 per share, on sales of $9 billion for the three months ended June 30, 2021, for a 16.7% bottom-line gain on sales growth of… […]
  • Evren Technologies earbud PTSD treatment device nabs FDA breakthrough device designation
    Evren Technologies this week announced that it received FDA breakthrough device designation for its Phoenix earbud device that treats PTSD. Gainesville, Fla.-based Evren Technologies designed the Phoenix device as a discreet earbud design that delivers transcutaneous auricular vagal nerve stimulation in a closed-loop system. It can be paired with the company’s PTSD symptom tracking app… […]
  • BD acquires resorbable polymer maker Tepha
    BD (NYSE:BDX) today announced that it has acquired resorbable polymer technology maker Tepha for an undisclosed amount. Franklin Lakes, N.J.–based BD said that it will use Lexington, Mass.–based Tepha’s resorbable polymer technology to accelerate growth of the company’s surgical mesh for soft tissue repair, reconstruction and regeneration. Tepha’s GalaFlex portfolio is also included in the acquisition.… […]
  • LifeSignals remote patient monitor wins FDA clearance
    LifeSignals today announced that it has received FDA 510(k) clearance for its LX1550 multi-parameter remote monitoring platform. Fremont, Calif.–based LifeSignals designed the LX1550 to continuously collect patient physiological data from home and in healthcare settings. The platform has a single-use wearable multi-parameter biosensor that records electrocardiography (ECG), heart rate, respiration rate, skin temperature and body… […]
  • Blackrock Neurotech and ClearPoint Neuro want to automate brain implant surgeries
    ClearPoint Neuro (NSDQ:CLPT) announced an agreement with Blackrock Neurotech to develop automated technologies for brain implant surgeries. The partnership will seek to develop an automated surgical solution for implanting brain-computer interfaces (BCIs) into patients with neurological disorders — including from paralysis, ALS, blindness and hearing loss. Solana Beach, Calif.–based ClearPoint Neuro said in a news… […]

Leave a Reply